“Revolutionary new molecules act on diabetes, obesity and cardiovascular disease at the same time”. Pierre Gourdy, diabetologist and professor at the University of Toulouse-III.
The development of two new classes of drugs – GLP-1 analogues and glifozins – has changed this approach. Treatment recommendations are no longer focused only on controlling blood sugar levels, but also on protecting the organs that can be damaged by diabetes: the arteries, the heart, the kidneys, the liver.